Trials / Completed
CompletedNCT07488624
Development and Multicenter Validation of a Novel Bio-Anatomical Staging System for Predicting Survival and Tailoring Adjuvant Therapy in ESCC After Neoadjuvant Chemoimmunotherapy.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 414 (actual)
- Sponsor
- Sichuan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this retrospective observational study is to build and validate a "bio-anatomical" prognostic model for patients with esophageal squamous cell carcinoma (ESCC) who underwent neoadjuvant immunochemotherapy (nICT) followed by radical surgery. The main question it aims to answer is: Can a "bio-anatomical" prognostic nomogram accurately predict overall survival and help guide individualized post-surgery treatment for ESCC patients after nICT better than traditional staging? Researchers will retrospectively analyze the clinical, pathological (including a new lymph node response indicator), and overall survival data of 414 eligible patients treated across three medical centers between 2019 and 2025.
Conditions
Timeline
- Start date
- 2025-09-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2026-03-23
- Last updated
- 2026-03-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07488624. Inclusion in this directory is not an endorsement.